Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Citations Over TimeTop 1% of 2020 papers
Abstract
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007 micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention.
Related Papers
- → The reproductive number of COVID-19 is higher compared to SARS coronavirus(2020)3,461 cited
- → Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia(2020)216 cited
- → Racing Towards the Development of Diagnostics for a Novel Coronavirus (2019-nCoV)(2020)32 cited
- → Wearing masks and the fight against the novel coronavirus (COVID-19)(2020)7 cited